

Chapter 1

Mood Disorders and Personality Disorders: Simplicity and Complexity

Joel Paris

Mood and Personality

Mood is a relatively straightforward concept. For the most part, mood varies as to whether it is high, low, or unstable. In contrast, personality is a very complex construct. It describes traits that affect behavior, thought, and emotion. Since personality describes normal variations, as opposed to abnormal states of mind, it is difficult to separate personality disorder (PD), which only some people have, from personality, which everyone has. Another difference is that while depressed or manic mood states can be scaled by clinicians, personality is often measured by self-report systems derived from factor analysis, such as the five-factor model [1], or by an extensive list of traits that can be clinically rated, as in DSM-5 [2]. Finally, mood disorders are often treated with drugs, while personality disorders usually require psychotherapy. For all these reasons, the construct of a mood disorder more readily appeals to clinicians who are looking for targets for treatment, while a personality disorder is seen as a murky and problematic idea.

Why the Mood Disorder Spectrum Has Expanded

Diagnostic constructs in psychiatry often reflect currently popular treatment options. Fifty years ago, a wide variety of clinical syndromes, most particularly somatic symptoms, were seen as reflections of abnormal mood or “masked depression” [3]. That diagnosis emerged at the same time as the wide use of tricyclic antidepressants

J. Paris, MD (✉)

Department of Psychiatry, Institute of Community and Family Psychiatry, McGill University,
4333 cote Ste. Catherine, Montreal, QC H3T 1E4, Canada

e-mail: joel.paris@mcgill.ca

© Springer Science+Business Media New York 2015

L.W. Choi-Kain, J.G. Gunderson (eds.), *Borderline Personality and Mood Disorders: Comorbidity and Controversy*, DOI 10.1007/978-1-4939-1314-5_1

and supported more frequent diagnoses of mood disorder [4]. Physicians naturally favor making diagnoses that lead to a prescription. Even then diagnoses that were indications for psychotherapy, an option that has always been expensive and not readily available, were less popular.

Theoretical ideas about mood disorders have also supported expansion of their scope. Forty years ago, Akiskal and McKinney [5] published a widely cited paper in *Science* arguing that depression was a single entity that only varies in severity. This construct was influential in the shaping of diagnostic manuals and supported the practice of treating a wider range of patients with antidepressants, a trend further strengthened by the development of selective serotonin reuptake inhibitors. At the same time, psychopathology of all kinds has been seen in the light of variations in mood [6].

Depression and Personality Disorder

While research on depression has been active from the 1950s, systematic empirical studies of personality disorders began to appear only in the 1980s [7]. At the time, mood disorder specialists challenged this research on the grounds that PDs could be better understood as depressive variants. Akiskal et al. [8] dismissed the diagnosis of borderline personality disorder (BPD), suggesting archly that since there was no border on which one could be “borderline,” this term was “an adjective in search of a noun.” Instead, Akiskal recommended that it be treated in much the same way as depression, i.e., with drugs. A counterattack from BPD specialists [9] argued that mood instability is a different phenomenon from sustained low mood. Moreover, evidence failed to show that antidepressants are particularly helpful in BPD [10]. Yet pharmacological treatment for these patients, not to speak of all psychiatric patients, became ubiquitous. To understand this shift in practice, we need to examine changes in the ideology of psychiatry as a medical specialty.

Psychotherapy and Psychopharmacology

Psychiatry used to be closely identified with psychotherapy. (Even today, the image of a bearded analyst behind a couch continues in New Yorker cartoons.) But beginning in the 1970s, the specialty underwent a paradigm shift [11]. Psychotherapy, in particular psychoanalysis, was seen as unscientific and retrograde. Since then, psychotherapy has been driven to the periphery of the profession. The new paradigm for psychiatry has been based on neuroscience, with treatment redefined as the clinical application of these principles [12]. Psychopathology would now be understood as a problem in neurochemistry or neurocircuitry and treated accordingly, largely with pharmacological interventions.

These conclusions were strongly supported by the pharmaceutical industry and by key opinion leaders drawn from academic psychiatry, who are often supported

by the industry [11]. One cannot deny that in choosing interventions for psychiatric patients, money talks. One never sees advertisements in journals supporting psychotherapy. In contrast, each of the latest antidepressants is heavily marketed, even if they differ by only a few atoms from those that have been used for years.

This trend led to the theoretical dominance of neurobiology and a decline in the provision of psychotherapy in psychiatry [13]. It supported diagnoses of mood disorders, which are widely understood to derive from abnormalities of neurotransmission that can be corrected by pharmacotherapy. It undermined interest in personality disorders, seen as poorly defined concepts treated with psychotherapies of doubtful value.

Moreover, patients themselves often prefer to be diagnosed with mood disorders. They may see depression (or bipolarity) as validating—a “chemical imbalance” for which they are not responsible. For some, personality disorder is seen as stigmatizing, implying they have a “bad personality.” It is possible to explain to patients what a personality disorder is and to reassure them that their condition is *less* chronic than many mood disorders, since research shows that most patients can be expected to get better with time [14]. But while some appreciate this feedback, particularly when antidepressants have not helped, others prefer a diagnosis of mood disorder and request more medication cocktails, showing little interest in talking therapy.

All these factors help to explain why the mood disorder model remains dominant, and some psychiatrists *never* diagnose a personality disorder. As shown by Zimmerman et al. [15] in a large clinical sample, PDs are highly prevalent but often missed. Of course it is also possible to misdiagnose a mood disorder as a PD, but that is less of an issue in the climate of contemporary psychiatry. Historically, the DSM system tried to encourage clinicians to think about personality by introducing multi-axial diagnosis. But Axis II was a failure, and it only succeeded in marginalizing the concept. In clinical reports, one often sees a statement that Axis II is “deferred,” i.e., to be ignored. In contemporary psychiatry, the roots of psychopathology in personality are downplayed, while many aspects of life are medicalized and understood as epiphenomena of an abnormal mood.

It is often said that PDs cannot be diagnosed in the presence of depression, since abnormal mood distorts personality, and PD features can disappear once mood goes back to normal. While this is sometimes true, when patients are followed over several months, most personality disorder symptoms remain stable even when mood returns to baseline [16]. Yet this idea continues to be taught to students, discouraging them from taking the careful life history required for making a PD diagnosis. It serves as another rationale for ignoring personality disorders, given that patients usually come for treatment when mood is low.

Bipolarity and Personality Disorder

The introduction of lithium for the treatment of bipolar disorder was a heroic chapter in the history of psychiatry. But lithium is a powerful drug that should only be prescribed when definitely required. The introduction of anticonvulsant mood

stabilizers, however, made it more possible to consider treating outpatients with milder problems as suffering from variants of bipolar disorder.

The expansion of the bipolar diagnosis has been one of the most influential developments in modern psychiatry [17, 18]. The bipolar spectrum has been extended to patients with a wide range of disorders, including chronic depression, substance abuse, and children with behavior disorders, with the mood instability of BPD seen particularly as lying in a bipolar spectrum [19]. Akiskal [20] continues to see BPD as fictional but now views it as a form of bipolarity rather than depression. Needless to say, Akiskal views psychotherapy as misguided and favors pharmacological treatment for almost all these patients.

Other advocates of the spectrum have expanded the boundaries of classic bipolar disorders into all forms of mood instability, sometimes called “soft bipolarity” [21, 22]. While psychiatrists have few problems recognizing bipolar I, bipolar II disorder requires the presence of hypomanic episodes [23], i.e., 4 days of continuous abnormal mood associated with behavioral symptoms. Yet if one reads journal articles carefully, mood swings of any kind can lead to either a diagnosis of bipolar II or of “bipolar disorder, not elsewhere classified” [19].

The trajectory of this expansion could eliminate the diagnosis of BPD as well as most other PDs. These ideas have also been very influential. It is rare to see a patient with the classical features of BPD who has not been given a bipolar diagnosis by someone. The idea that mood swings, even when brief, are a sign of bipolarity has also gained currency among primary care physicians. Yet expansion of the spectrum has not been supported by controlled trials showing that patients with “soft bipolar” symptoms benefit from mood stabilizing medication [24] or that patients with PDs benefit consistently from their prescription [10]. Moreover, there is evidence that affective instability (AI) in BPD could be a unique phenotype and differs from classical hypomania [25]. When patients have AI, mood shifts by the hour, not by the week, and does not arise spontaneously but is strongly related to interpersonal events and stressors [26].

Reductionism and Medicalization

The decline of the concept of personality disorder is an incidental effect of a larger trend in psychiatry. While PDs, like other mental disorders, are associated with biological variations, they are too complex to fit a reductionistic neurobiological model. It does not make sense to reduce maladaptive life choices to neurochemistry. Once one conceptualizes a problem as a PD, one has to give serious consideration to psychosocial factors in etiology and treatment. In contrast, when one sees patients as suffering from depression or bipolarity, it is possible to consider them as equivalent to medical disorders. These diagnoses may also be perceived as reducing stigma.

Yet depression is defined so broadly these days that it describes all forms of human unhappiness [27]. The assumption seems to be that life should be happy, and that if isn't, you have a mental disorder. This perspective also fails to separate depression into melancholic cases in which medication is necessary and non-melancholic cases in which it may not be required [28]. In the same way, bipolarity medicalizes variations in personality traits and has come to be a code word, in both medical and common parlance, to describe people who are moody and difficult.

Contemporary psychiatry hopes to expand its triumphs in the golden years of psychopharmacology and has made a bet that neuroscience research will eventually solve the mystery of mental illness. Personality disorders are rejected because they remind people of the bad old days when psychoanalytic concepts dominated the field. The author of a prominent textbook on the history of psychiatry [29] referred to borderline personality as a concept that only Woody Allen would take seriously.

Yet the loss of a personality disorder construct could have serious consequences for patients. Focusing on depression avoids the assessment of life course, which is necessary to understand the complex impact of personality on psychopathology. Also, current evidence shows that drugs only palliate the symptoms of PD, which are better managed with specific forms of psychotherapy [30]. Mood is the hammer that makes everything look like a nail.

Future Prospects

While research on genetics, neuroimaging, or neurotransmitters has enriched psychiatric theory, these findings have not yet had any clinical application [31]. One reaction to the slow progress in the field is to assume that concepts we know something about, like variations in mood, can explain why patients suffer from complex behavioral symptoms.

Psychiatrists are physicians who have been trained to see the body as a machine. They know a good deal about chemistry and physiology but rarely have a strong background in psychology. Some physicians are uncomfortable with the complexity that social sciences bring to practice. They have been trained to reach firm conclusions after conducting differential diagnosis and to offer treatment that is targeted and specific. They are uncomfortable with complex interactions between multiple risk factors that determine psychopathology. They pay only lip service to the biopsychosocial approach [32], which remains a useful model for studying complexity.

If mood disorder advocates are right, the concept of personality disorder should be jettisoned and psychotherapy abandoned as a treatment. But if they are wrong, diagnosing almost every PD patient with a mood disorder will lead to incorrect and harmful treatment. Thus, the problem of the boundaries of mood and personality disorders is central to the identity of psychiatry and to its future.

References

1. Costa PT, Widiger TA, editors. *Personality disorders and the five factor model of personality*. 3rd ed. Washington, DC: American Psychological Association; 2012.
2. American Psychiatric Association. *Diagnostic and statistical manual of mental disorders*, text revision. 5th ed. Washington, DC: American Psychiatric Press; 2013.
3. Lesse S. Masked depression—a diagnostic and therapeutic problem. *Dis Nerv Syst*. 1968;29:169–73.
4. Shorter E. *Before prozac*. New York: Oxford University Press; 2009.
5. Akiskal HS, McKinney Jr WT. Depressive disorders: toward a unified hypothesis. *Science*. 1973;182:20–9.
6. Angst J, Merikangas K. The depressive spectrum: diagnostic classification and course. *J Affect Disord*. 1997;45:31–9.
7. Millon T. On the history and future study of personality and its disorders. *Annu Rev Clin Psychol*. 2012;8:1–19.
8. Akiskal HS, Chen SE, Davis GC. Borderline: an adjective in search of a noun. *J Clin Psychiatry*. 1985;46:41–8.
9. Gunderson JG, Phillips KA. A current view of the interface between borderline personality disorder and depression. *Am J Psychiatry*. 1991;148:967–75.
10. Stoffers J, Völlm BA, Rütcke G, Timmer A, Huband N, Lieb K. Pharmacological interventions for borderline personality disorder. *Cochrane Database Syst Rev*. 2010;(6):CD005653. doi:[10.1002/14651858.CD005653.pub2](https://doi.org/10.1002/14651858.CD005653.pub2).
11. Carlat D. *Unhinged*. New York: Free Press; 2010.
12. Insel TR, Quirion R. Psychiatry as a clinical neuroscience discipline. *JAMA*. 2002;294:2221–4.
13. Mojtabai R, Olfson M. National trends in psychotherapy by office-based psychiatrists. *Arch Gen Psychiatry*. 2008;65:962–70.
14. Gunderson JG, Stout RL, McGlashan TH, Shea MT, Morey LC, Grilo CM, et al. Ten-year course of borderline personality disorder: psychopathology and function from the Collaborative Longitudinal Personality Disorders Study. *Arch Gen Psychiatry*. 2011;68:827–37.
15. Zimmerman M, Rothschild L, Chelminski I. The prevalence of DSM-IV personality disorders in psychiatric outpatients. *Am J Psychiatry*. 2005;162:1911–8.
16. Lopez-Castroman J, Galfalvy H, Currier D, Stanley B, Mann JJ, Oquendo MA. Personality disorder assessments in acute depressive episodes: stability at follow-up. *J Nerv Ment Dis*. 2012;200:526–30.
17. Angst J, Gamma A. A new bipolar spectrum concept: a brief review. *Bipolar Disord*. 2002;4:11–4.
18. Akiskal HS. The bipolar spectrum—the shaping of a new paradigm in psychiatry. *Curr Psychiatry Rep*. 2002;4:1–3.
19. Paris J. *The bipolar spectrum: diagnosis or Fad?* New York: Routledge; 2012.
20. Akiskal HS. Demystifying borderline personality: critique of the concept and unorthodox reflections on its natural kinship with the bipolar spectrum. *Acta Psychiatr Scand*. 2004;110:401–7.
21. Ghaemi SN, Ko JY, Goodwin FK. “Cade’s disease” and beyond: misdiagnosis, antidepressant use, and a proposed definition for bipolar spectrum disorder. *Can J Psychiatry*. 2002;47:125–34.
22. Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey Replication. *Arch Gen Psychiatry*. 2007;64:543–52.
23. Parker G, editor. *Bipolar-II disorder. Modeling, measuring and managing*. 2nd ed. Cambridge: Cambridge University Press; 2012.
24. Patten S, Paris J. The bipolar spectrum—a bridge too far? *Can J Psychiatry*. 2008;53:762–8.

25. Koenigsberg H. Affective instability: toward an integration of neuroscience and psychological perspectives. *J Pers Disord.* 2010;24:60–82.
26. Russell J, Moskowitz D, Sookman D, Paris J. Affective instability in patients with borderline personality disorder. *J Abnorm Psychol.* 2007;116:578–88.
27. Horwitz AV, Wakefield JC. *The loss of sadness: how psychiatry transformed normal sorrow into depressive disorder.* New York: Oxford University Press; 2007.
28. Parker G. Beyond major depression. *Psychol Med.* 2005;35:467–74.
29. Shorter E. *A history of psychiatry.* New York: Wiley; 1997.
30. Paris J. Effectiveness of differing psychotherapy approaches in the treatment of borderline personality disorder. *Curr Psychiatry Rep.* 2010;12:56–60.
31. Hyman SE. The diagnosis of mental disorders: the problem of reification. *Annu Rev Clin Psychol.* 2010;6:155–79.
32. Engel GL. The clinical application of the biopsychosocial model. *Am J Psychiatry.* 1980; 137:535–44.